Clinical trial · Interventional
Suprachoroidal Administration in Subjects With Metastases to the Choroid
A Phase 2, Open-Label, Dose Escalation Trial Assessing the Safety, Tolerability, and Treatment Effect of Belzupacap Sarotalocan (AU-011) With Suprachoroidal Administration in Subjects With Metastases to the Choroid
NCT06643884CI-TRIAL-00105528recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Eye Cancer | Malignant Eye Neoplasm | ALIAS | 0.90 |
| Primary Cancer | Primary Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AU-011 | Drug | — | UNRESOLVED |
| Laser | Device | — | UNRESOLVED |
| SCS Microinjector | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (7)
- type
- EXPERIMENTAL
- label
- 80 micrograms of bel-sar
- description
- 1 Cycle AU-011 with a dose of 80 micrograms
- interventionNames
- Drug: AU-011
- Device: SCS Microinjector
- Device: Laser
- type
- EXPERIMENTAL
- label
- 140 micrograms of bel-sar
- description
- 1 Cycle AU-011 with a dose of 140 micrograms
- interventionNames
- Drug: AU-011
- Device: SCS Microinjector
- Device: Laser
- type
- EXPERIMENTAL
- label
- 200 micrograms of bel-sar with one cycle
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Have a clinical diagnosis of Metastases to the Choroid, from a histopathologically or cytologically confirmed tumor. * Have at least one Metastases to the Choroid in the study eye Exclusion Criteria: * Active ocular infection or disease. * Must not have evidence of a primary tumor or metastatic lesion in the brain requiring treatment with radiation therapy per the primary treating oncologist's assessment. * Must not be planning or expecting to switch/add systemic antineoplastic therapies during treatment
References
Publications (0)
Data not yet available
No reference posted for this study.